Thalidomide for unresectable hepatocellular cancer with optional interferon alpha-2a upon disease progression
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interferon alpha (Primary) ; Thalidomide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 11 Feb 2013 Biomarkers information updated
- 14 Dec 2005 Status change
- 03 Sep 2005 New trial record.